Progress in the Prevalence, Classification and Drug Resistance Mechanisms of Methicillin-Resistant Staphylococcus aureus
Zhuru Hou,Ling Liu,Jianhong Wei,Benjin Xu
DOI: https://doi.org/10.2147/IDR.S412308
2023-05-25
Infection and Drug Resistance
Abstract:Zhuru Hou, 1, 2, &ast Ling Liu, 2– 4, &ast Jianhong Wei, 1 Benjin Xu 2– 4 1 Department of Basic Medicine, Fenyang College of Shanxi Medical University, Fenyang, People's Republic of China; 2 Key Laboratory of Lvliang for Clinical Molecular Diagnostics, Fenyang, People's Republic of China; 3 Department of Medical Laboratory Science, Fenyang College of Shanxi Medical University, Fenyang, People's Republic of China; 4 Department of Clinical Laboratory, Fenyang Hospital of Shanxi Province, Fenyang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jianhong Wei, Department of Basic Medicine, Fenyang College of Shanxi Medical University, Fenyang, 032200, People's Republic of China, Email Benjin Xu, Department of Medical Laboratory Science, Fenyang College of Shanxi Medical University, Fenyang, 032200, People's Republic of China, Email Staphylococcus aureus is a common human pathogen with a variety of virulence factors, which can cause multiple infectious diseases. In recent decades, due to the constant evolution and the abuse of antibiotics, Staphylococcus aureus was becoming more resistant, the infection rate of MRSA remained high, and clinical treatment of MRSA became more difficult. The genetic diversity of MRSA was mainly represented by the continuous emergence of epidemic strains, resulting in the constant changes of epidemic clones. Different classes of MRSA resulted in different epidemics and resistance characteristics, which could affect the clinical symptoms and treatments. MRSA had also spread from traditional hospitals to community and livestock environments, and the new clones established a relationship between animals and humans, promoting further evolution of MRSA. Since the resistance mechanism of MRSA is very complex, it is important to clarify these resistance mechanisms at the molecular level for the treatment of infectious diseases. We firstly described the diversity of SCC mec elements, and discussed the types of SCC mec , its drug resistance mechanisms and expression regulations. Then, we described how the vanA operon makes Staphylococcus aureus resistant to vancomycin and its expression regulation. Finally, a brief introduction was given to the drug resistance mechanisms of biofilms and efflux pump systems. Analyzing the resistance mechanism of MRSA can help study new anti-infective drugs and alleviate the evolution of MRSA. At the end of the review, we summarized the treatment strategies for MRSA infection, including antibiotics, anti-biofilm agents and efflux pump inhibitors. To sum up, here we reviewed the epidemic characteristics of Staphylococcus aureus , summarized its classifications, drug resistance mechanisms of MRSA (SCC mec element, vanA operon, biofilm and active efflux pump system) and novel therapy strategies, so as to provide a theoretical basis for the treatment of MRSA infection. Keywords: biofilm, efflux pump, MRSA, prevalence, resistance mechanism, SCC mec Staphylococcus aureus ( S. aureus ) is a kind of gram-positive conditional pathogen that widely exists in human living environment. It can asymptotically colonize the nasal cavity of normal humans. However, when the body's immune function is low, it can infect local skin and soft tissues, and even enter deep tissues and blood, causing systemic infections such as pneumonia, endocarditis, osteomyelitis and even bacteremia. 1 According to the molecular epidemiological evidences, methicillin-susceptible Staphylococcus aureus (MSSA) becomes methicillin-resistant Staphylococcus aureus (MRSA) after evolving several times. MRSA is one type of S. aureus carrying mecA/mecC gene or oxacillin MIC value≥4μg/mL, 2 which has become a multidrug-resistant bacterium that seriously threatens human health. With rapid spread and complex drug resistance mechanisms, case fatality rate in patients with clinical MRSA infection is high. Nearly 150,000 MRSA infections were reported annually in European Union countries, resulting in more than 7000 deaths. 3 And in China, the infection rate of MRSA had been maintained at over 30% for the past five years according to data from CHINET surveillance system. Otherwise, bacteremia caused by MRSA infection is a common cause of global bloodstream infections, with a mortality rate of 32.4%, and even higher in developing countries. 4 Therefore, it is extremely important to understand the prevalence of MRSA and explore strategies for preventing and treating MRSA infection. In this paper, the prevalence status and resistance mechanisms of MRSA are reviewed -Abstract Truncated-
pharmacology & pharmacy,infectious diseases